Shareholder Alert: The Ademi Firm investigates whether Akero Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Group 1 - Akero shareholders will receive $54.00 per share, equating to an equity value of approximately $4.7 billion [2] - Shareholders are entitled to a contingent value right for an additional $6.00 per share if Akero's drug efruxifermin receives full U.S. regulatory approval by June 30, 2031 [2] - Akero insiders will benefit significantly from change of control arrangements as part of the transaction [2] Group 2 - The transaction agreement imposes a significant penalty on Akero for accepting competing bids, which raises concerns about the board's fiduciary duties [3] - An investigation is underway regarding the conduct of Akero's board of directors in relation to their obligations to shareholders [3] - The Ademi Firm specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [3]